Annual drug shortages are common in the US and indeed throughout the world and can be attributed to a few key issues. Experts have pointed out how policy can assist in regulating the production, manufacturing, distribution, and purchase of essential drugs to prevent shortages of critical drugs,
Optimizing cell line development (CLD) for next-generation biologics is crucial to meet the rapidly growing demand for novel therapeutic modalities. As the biologics sector evolves, it's imperative to address potential bottlenecks in the development process through strategic enhancements and
Freeline Therapeutics, known for its pioneering work in gene therapy, has unveiled a new identity and an expanded mission, rebranding itself as Spur Therapeutics. This transformation marks a significant step towards a broader and more ambitious vision that includes tackling both rare genetic
In a move that reaffirms its position as a powerhouse in the life sciences sector, Merck has made a resounding statement with a substantial €180 million investment to expand its distribution center in Schnelldorf, Germany. This ambitious project has nearly doubled the existing facility's size b
As the first quarter of 2024 closed, the biopharma sector wasn't just riding the wave of excitement that accompanies groundbreaking scientific discoveries—it was also navigating the tumultuous waters of the financial markets. With M&A activity surging by a staggering 71 percent in &
Throughout 2023 and 2024, the U.S. Food and Drug Administration (FDA) played a pivotal role in the pharmaceutical and biotechnology sectors, not only by approving a significant number of new drugs but also by pushing the boundaries of innovation. These two years were marked by a notable surge in
As the field of medical research forges ahead, certain pioneering companies are facing a formidable hurdle. MMJ BioPharma Labs and MMJ International Holdings, at the forefront of developing cannabis-based pharmaceuticals, find themselves entangled in a problematic scenario with the Drug Enforcement
Cancer treatments have long been a complex array of procedures with varying degrees of success. However, groundbreaking research from the University of Houston, spearheaded by Navin Varadarajan and his team, has shone a light on a new horizon for cancer therapy. They have identified CD8-fit T
Recent actions by U.S. House lawmakers have cast a spotlight on GenScript, a Chinese Contract Development and Manufacturing Organization (CDMO), and its cell therapy division, Legend Biotech, amidst concerns of potential Chinese Communist Party (CCP) influence within the American biotech realm.
As the battle against cancer continues, one particular area showing remarkable strides is colorectal cancer research and treatment. With over 195 key players in the industry, a testament to the competitive yet collaborative nature of the field, advancements are moving at an incredible pace. From
